Belviq Tablet® Post Marketing Surveillance Protocol
NCT03741010 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000
Last updated 2018-11-26
Summary
Post-marketing surveillance of Lorcaserin
Conditions
Sponsors & Collaborators
-
IlDong Pharmaceutical Co Ltd
lead INDUSTRY
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-02-02
- Primary Completion
- 2021-02-01
- Completion
- 2021-02-01
More Related Trials
-
Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic
NCT03552107 ·Status: COMPLETED
-
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
NCT06584916 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of IQP-VV-102 in Weight Management
NCT01681069 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State
NCT00828724 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Litramine in 1 Year Weight Loss Study
NCT03227276 ·Status: COMPLETED ·Phase: NA
-
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
NCT00395135 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
NCT04657016 ·Status: COMPLETED ·Phase: PHASE3
-
Benefit and Tolerability of IQP-LU-104 in Weight Loss
NCT03888911 ·Status: COMPLETED ·Phase: NA
-
Saxenda: Underlying Mechanisms and Clinical Outcomes
NCT02944500 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects
NCT01597609 ·Status: COMPLETED ·Phase: PHASE1
-
3mg Liraglutide for Overweight or Obesity
NCT03885297 ·Status: COMPLETED
-
Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)
NCT00533481 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
NCT01550926 ·Status: COMPLETED ·Phase: PHASE1
-
STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY
NCT04616339 ·Status: COMPLETED ·Phase: PHASE1
-
To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity
NCT03795701 ·Status: COMPLETED ·Phase: NA
-
To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake
NCT00829140 ·Status: COMPLETED ·Phase: PHASE1
-
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
NCT03479762 ·Status: COMPLETED
-
Saxenda in Obesity Services (STRIVE Study)
NCT03036800 ·Status: COMPLETED ·Phase: PHASE4
-
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
NCT00603902 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
NCT03100058 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066515 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Liraglutide 3.0 on Body Fat Distribution
NCT03038620 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
NCT04904913 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.
NCT04589130 ·Status: UNKNOWN ·Phase: PHASE4